by Postpartum depression (PPD) is a mood disorder that can occur after childbirth. Symptoms may include excessive crying, anxiety, irritability, constant sadness, and fatigue. PPD drugs aim to treat symptoms such as sadness, irritability, lack of energy, and feelings of worthlessness that occur during this period. Common drugs for PPD include antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Other medications may also be prescribed depending on the severity of symptoms. The global postpartum depression drug market is estimated to be valued at US$ 6.65 Bn in 2023 and is expected to exhibit a CAGR of 3.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Rising prevalence of postpartum depression is expected to drive the growth of the global postpartum depression drug market over the forecast period. According to the WHO, postpartum depression affects 10-15% of women globally and half of them do not seek help. In the US alone, around 450,000 annually experience symptoms of postpartum depression. Increasing awareness about the condition and availability of effective treatment options are expected to boost the demand for drugs for postpartum depression treatment. Also, rapid entry of generic drugs is anticipated to fuel market growth by making therapy affordable for more patients. However, factors such as reluctance to seek treatment due to fear of stigma and poor diagnosis may restrain market growth.
Segment Analysis
The postpartum depression drug market is dominated by the antidepressant segment which holds around 50% share. Antidepressants are the first line of treatment for postpartum depression as they are effective and have lesser side effects as compared to other therapies. Moreover, research studies have shown that selective serotonin reuptake inhibitors (SSRIs) are the most common therapy recommended by doctors to new mothers experiencing postpartum depression symptoms. Well-known SSRI drugs prescribed includes fluoxetine and sertraline.
PEST Analysis
Political: Healthcare reforms in various countries are pushing for more funding into postpartum depression treatment and awareness. Many nations have also implemented paid maternity leave policies which encourage new mothers to seek help.
Economic: Rising income levels have boosted healthcare spending on mental illnesses. Growing public awareness is also driving the demand for specialty drugs to treat postpartum depression.
Social: Reducing social stigma around perinatal mental health issues has encouraged more women to get screened and diagnosed early. Family and partner support plays a vital role in therapy compliance.
Technological: Mobile apps and telehealth services have emerged as effective tools to monitor symptoms from home and adhere to treatment plans remotely under medical supervision.
Key Takeaways
The Global Postpartum Depression Drug Market is expected to witness high growth. Regional analysis comprises North America dominates currently due to high diagnosis and treatment rates. Factors such as favorable reimbursements and extensive patient awareness drives contribute to the large market share. However, Asia Pacific is poised to be the fastest growing region owing to improved access to healthcare facilities and increasing adoption of antidepressants.
Key players operating in the postpartum depression drug market are Sun Pharma, UCB Farchim SA, Yangtze River Pharmaceutical (Group) Co., Ltd., Livzon Pharmaceutical Group Inc., Nanjing Sanhome Pharmaceutical Co.,Ltd., PKU Healthcare Corp., Ltd., Qilu Pharmaceutical Co., Ltd., Jilin Huakang Pharmaceutical Co., Ltd., Sichuan Hengrui Pharmaceutical Co., Ltd., Shaixi Taiyuan Pharmaceutical Co., Ltd., Guangdong Guoyuan Sinopharm Co., Ltd., Suzhou Dawnrays Pharmaceutical Co., Ltd., Zhejiang Zhebei Pharmaceutical Co., Ltd., Nanjing Chang’ao Pharmaceutical Co., Ltd., Xinhua Pharmaceutical (Gaomi) Co., Ltd..
Note:
Source: Coherent Market Insights, Public sources, Desk research
We have leveraged AI tools to mine information and compile it
